Beta Bionics CFO Feider Stephen sold 6,675 shares at $19.11 per share on September 2, 2026. His disclosed ownership after the transaction was 159,378 shares, giving investors the stated post-sale position of a senior executive in Beta Bionics and a clear reference for tracking his remaining holdings.
Key Highlights
- The transaction took place on September 2, 2026.
- Feider Stephen is Beta Bionics’ Chief Financial Officer.
- His disclosed ownership after the sale was 159,378 shares.
Beta Bionics, Inc. (NASDAQ: BBNX) CFO Feider Stephen sold 6,675 shares at $19.11 per share. His disclosed ownership following the transaction was 159,378 shares. The transaction occurred on September 2, 2026, with Stephen identified as Beta Bionics’ Chief Financial Officer. The reported sale involved shares of Beta Bionics at the stated per-share price.
September 2 Share Sale Stephen’s
The ownership figure was reported following the transaction. Beta Bionics identified Stephen by name and executive role in connection with the share sale. The reported price was $19.11 for each share sold, while the transaction quantity was 6,675 shares.
FAQs
Q: How many Beta Bionics shares did Feider Stephen sell?
A: Beta Bionics CFO Feider Stephen sold 6,675 shares. The transaction price was $19.11 per share, and it occurred on September 2, 2026.
Q: What was the reported impact of the BBNX CFO share sale?
A: The filing reports that Feider Stephen owned 159,378 Beta Bionics shares after the transaction. It also records the sale of 6,675 shares at $19.11 per share.
Q: How many Beta Bionics shares does Feider Stephen own after the sale?
A: Following the reported transaction, Feider Stephen owned 159,378 Beta Bionics shares. The filing identifies him as the company’s Chief Financial Officer and records the sale in the Form 4.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.